Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.99%
1,093.81
+10.77
+0.99%
—1,083.041,082.631,099.011,080.59——
SIXC
Communications
SIXC
Communications
SIXC
+1.06%
608.77
+6.39
+1.06%
—602.38602.38609.75599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.96%
1,254.81
+11.98
+0.96%
—1,242.831,229.311,258.881,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.76%
1,761.11
+47.29
+2.76%
—1,713.821,715.471,763.111,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.40%
642.58
+2.59
+0.40%
—639.99636.98644.04631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.63%
851.13
+13.67
+1.63%
—837.46840.30852.55840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.76%
217.98
+3.76
+1.76%
—214.22214.22218.25214.05——
SIXT
Technology
SIXT
Technology
SIXT
+0.23%
3,211.83
+7.45
+0.23%
—3,204.383,215.043,217.443,159.90——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.55%
948.98
+23.60
+2.55%
—925.38927.91949.76927.91——
SIXV
Health care
SIXV
Health care
SIXV
+2.20%
1,474.52
+31.81
+2.20%
—1,442.711,443.011,477.901,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.30%
2,392.12
+30.78
+1.30%
—2,361.342,391.002,399.182,354.52——
Q1 2026 earnings • released • EPS beat +6.38% • Revenue beat +3.50%
See results
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$707.06
+3.02%
(+20.70) 1D
$709.52
+0.35% (+2.46)
After hours
Closed: Apr 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
$693.08
High
$708.44
Low
$688.94
Mkt. cap
74.13B
Avg. vol.
603.55K
Volume
0.00
Dividend
0.53%
Quarterly dividend
$0.94
Ex dividend date
Nov 20, 2025
P/E ratio
16.88
52-wk high
$821.11
52-wk low
$476.49
EPS
$41.89
Beta
0.40
Shares outstanding
103.90M
No. of employees
15K
News stories
From sources across the web
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.4K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Last report
Apr 29, 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
9.47/ (8.90 est.)USD
+6.38%beat
Revenue / Estimate
3.61B/ (3.48B est.)USD
+3.50%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.68B
3.75B
3.88B
3.61B
Cost of goods sold
1.95B
2.00B
2.21B
-
Cost of revenue
1.95B
2.00B
2.21B
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
634.20M
657.80M
775.00M
-
Operating expense
634.20M
647.80M
775.00M
-
Total operating expenses
2.59B
2.64B
2.99B
-
Operating income
1.09B
1.11B
898.60M
-
Other non operating income
18.20M
3.00M
958.50M
-
EBT including unusual items
1.52B
1.76B
1.04B
-
EBT excluding unusual items
1.28B
1.27B
2.04B
-
Income tax expense
127.10M
303.30M
199.10M
-
Effective tax rate
8.37%
17.20%
19.08%
-
Other operating expenses
-
-10.00M
-
-
Net income
1.39B
1.46B
844.60M
-
Net profit margin
37.86%
38.89%
21.74%
20.17%
Earnings per share
12.89
11.83
11.44
9.47
Interest and investment income
174.80M
175.10M
193.30M
-
Interest expense
-3.60M
-19.30M
-12.20M
-
Net interest expenses
171.20M
155.80M
181.10M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
1.22B
1.25B
1.04B
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer